v3.26.1
Note 13 - Net Loss per Share - Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Net loss $ (11,687) $ (4,439) $ (25,596) $ (31,347)
Less: Series B Convertible Preferred Stock dividends earned (3,028) (3,449) (12,747) (12,559)
Net loss attributable to Lucid Diagnostics Inc. common stockholders $ (14,715) $ (7,888) $ (38,343) $ (43,906)
Weighted average common shares outstanding, basic and diluted (in shares) 183,124,412 98,989,161 161,729,458 83,976,182
Net loss per share - basic and diluted (in dollars per share) [1] $ (0.08) $ (0.08) $ (0.24) $ (0.52)
Series B and B-1 Preferred Stock [Member]        
Less: Series B Convertible Preferred Stock dividends earned $ (3,028) $ (3,449) $ (12,747) $ (12,559)
[1] Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.